Sprint Bioscience AB (publ) (SPRINT)
Free
No email, no account, no signup.
Pulling latest news for Sprint Bioscience AB (publ)…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Signal
NEUTRAL
Sentiment
7/10
Risk
7/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Order analysis – $4.99
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Sentiment is described as broadly **positive** after the Gilead deal, focusing on perceived undervaluation, future milestones, and new partnering. Social chatter appears relatively limited and news-driven.
Exchange
Nasdaq First North Premier Growth Market
Type
Biotech
Sector
Biotech (preclinical oncology drug development)
Market Cap
$25M
Market sentiment
Sentiment is described as broadly **positive** after the Gilead deal, focusing on perceived undervaluation, future milestones, and new partnering. Social chatter appears relatively limited and news-driven.
Why NEUTRAL ?
- **REVIEW** due to mixed inputs: strong validation via the Gilead deal, but still high preclinical risk.
- Cash figures differ across sources; the next report is important to confirm cash and burn.
- Upside is option-like via new deals/milestones, but timing/probability is uncertain.
- Hold/watch; consider adding only after confirmed new deals or milestones.
Recent News
- Since 2026-04-06: The NNMT program was expanded to kidney failure (2026-04-07). The 2025 annual report was published (2026-04-15) and reiterated a strong liquidity position (cash ~SEK 126.7m at the start of 2026 per reported figures). The VRK1 program reported positive preclinical proof-of-concept results (2026-04-16). The strategic STK25 evaluation with EDDC was completed and the alternative inflammatory indication track was discontinued; the program is now fully focused on the primary MASH indication (2026-04-16/17). New preclinical DCPS data were presented at AACR (2026-04-17).
Bull case
- **Momentum** and higher visibility after the **Gilead** TREX1 deal
- Upcoming report may confirm improved cash/burn after the upfront
- Preclinical data points (e.g., DCPS/NNMT) can support interest
Unlock to read more →
Bear case
- Limited near-term news flow can trigger a **pullback** after deal-driven strength
- **Low liquidity** can amplify volatility
- Market may discount milestones as distant and uncertain
Unlock to read more →
Catalysts
15 Jun 2026 — BIO 2026 partnering focus
Dilution Risk
Assessment: Medium
Order analysis – $4.99
Save hours of research. $4.99.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Sprint Bioscience AB (publ) – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.